600161.SH
Beijing Tiantan Biological Products Corp. Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 12.57
+1.21%Oct 29, 2026, 08:57 UTC
Tiantan Biological reported first-three-quarter revenue of CNY 3.852 billion, down 13.73% year over year, and net profit attributable to shareholders of CNY 428 million, down 47.72%.
Source:Oct 29, 2026, 08:57 UTC
Tiantan Biological reported third-quarter revenue of CNY 1.257 billion, down 7.23% year over year, and net profit attributable to shareholders of CNY 129 million, down 30.65%.
Source:Oct 8, 2026, 09:01 UTC
Chengdu Rongsheng, a subsidiary of Tiantan Biological, completed a Phase III clinical trial of human coagulation factor IX and obtained the trial summary report.
Source:Sep 7, 2026, 09:25 UTC
Tiantan Biological's four subsidiaries received single plasma collection licenses from the Gansu Provincial Health Commission, allowing them to operate.
Source:Aug 28, 2026, 09:18 UTC
Tiantan Biological announced a cash dividend of 1 yuan per 10 shares (tax included) based on the total share capital of 1.977 billion shares as of the end of June 2026, with a total dividend amount of 198 million yuan (tax included).
Source:Jul 14, 2026, 10:54 UTC
Tiantan Biological announced its semi-annual net profit for 2026, reporting a significant decline.